From £7.99 per month
ShareProphets
The one stop source for breaking news, expert analysis, and podcasts on fast-moving AIM and LSE listed shares

MINDING THE LSE’S BUSINESS

Join for as low as £7.99 per month

With ShareProphets’ membership, you receive:

• All premium articles

• Tom Winnifrith’s Bearcast

• Access to all the entire nearly 10 year archive

• ShareProphets Daily Newsletter

Fusion Antibodies – argues a “delighted” by “enthusiasm” shown placing, but does it really provide vast growth potential or is it to be needed to ‘keep the lights on’?…

By Steve Moore | Tuesday 18 March 2025


Disclosure: I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from ShareProphets). I have no business relationship with any company whose stock is mentioned in this article.


Most recently writing on company describing itself as “specialists in pre-clinical antibody discovery, engineering and supply for both therapeutic drug and diagnostic applications” Fusion Antibodies (FAB), in December with the shares soaring to above 6p I concluded that I remained unconvinced of a sustainable funding platform and to still avoid. The shares went on to exceed 10p in January, most recently closed at 6.75p and now a placing announcement…

Premium content is for paid subscribers only
ShareProphets is reader-supported journalism

Become a member starting at £6.99 per month for all articles, the Bearcast, and our seven year archive.


Filed under:



Subscribe to our newsletter

Daily digest of our latest stories.



Search ShareProphets

Market News

Complete Coverage

Recent Comments

That Was the Week that Was

Sunday »

EZJ

BUY Easyjet

 

PDL

Petra Diamonds Remains a Short

 

Boom

Failed fund manager for PM!

 

Oil-Rig

Oilman Jim: is this legal?

Time left: 12:03:06